CD274 and non-small cell lung carcinoma: For patients who have unresectable advanced or metastatic NSCLC with PD-L1 expression ≥ 50% and no targetable genomic alterations, the preferred first-line therapies listed in US National Comprehensive Cancer Network (NCCN) guidelines include pembrolizumab, atezolizumab, or cemiplimab-rwlc as monotherapy or pembrolizumab-combination therapy, the latter chosen according to NSCLC histopathology [7].